Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP and CFO | February 18, 2025 | February 19, 2025 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 18, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 225,808 |
Ending reported balance
After 2025-02-19 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2025-02-18 · Sale · Disposed 2,900 · Balance 247,248 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2025-02-18 · Sale · Disposed 14,630 · Balance 232,618 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2025-02-19 · Exercise / conversion · Acquired 18,533 · Balance 251,151 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 4 · 2025-02-19 · Exercise / conversion · Acquired 16,865 · Balance 268,016 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 5 · 2025-02-19 · Exercise / conversion · Acquired 15,642 · Balance 283,658 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 6 · 2025-02-19 · Exercise / conversion · Acquired 9,483 · Balance 293,141 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 7 · 2025-02-19 · Sale · Disposed 67,333 · Balance 225,808 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.09 · Expires 2028-02-15 | Direct | 31,285 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Exercise / conversion · Disposed 15,642 · Balance 31,285 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.12 · Expires 2029-02-21 | Direct | 37,934 |
Reported balance
After 2025-02-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-19 · Exercise / conversion · Disposed 9,483 · Balance 37,934 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.26 · Expires 2026-02-22 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-19 · Exercise / conversion · Disposed 16,865 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.55 · Expires 2027-02-28 | Direct | 37,067 |
Reported balance
After 2025-02-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-19 · Exercise / conversion · Disposed 18,533 · Balance 37,067 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,371 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 404 · Balance 1,371 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 681 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 681 · Balance 681 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,355 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 23 · Balance 1,355 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 57 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 57 · Balance 57 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nuance Communications, Inc.
Report date March 04, 2022 · Filed March 04, 2022
Section 16 reporting ended · disclosed 2022-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-04 · Disposition to issuer · Disposed 4,519 · Balance 53,492 F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award. Row 2 · 2022-03-04 · Disposition to issuer · Disposed 53,492 · Balance 0 F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award.
F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,572 | $47.14 | $356,927.42 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,316 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.993 to $47.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,219 | $47.29 | $57,646.51 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,888 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 7,572 | $7.39 | $55,957.08 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 45,404 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002032 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,404 Underlying: Common Stock · 45,404 shares Expires 2033-02-14 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 17,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002032 · doc4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,449 Underlying: Common Stock · 17,449 shares Expires 2027-02-14 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 14,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002032 · doc4.xml · derivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,901 Underlying: Common Stock · 14,901 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:49 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 827 | $0.00 Strike: $345.59 | $0.00 |
DisclosureSEC source: 0001127602-23-000745 · form4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 827 shares Expires 2033-01-03 F2 · shares: Options fully vest on January 3, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:49 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 318 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000745 · form4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 3, 2024 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 13,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-000047 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,134 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. F1 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. F1 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 4,042 | $46.27 | $187,023.34 |
DisclosureSEC source: 0001225208-23-000047 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,382 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-000047 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 18:37 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 144 | $0.00 Strike: $334.57 | $0.00 |
DisclosureSEC source: 0001127602-22-026413 · form4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144 Underlying: Common Stock · 144 shares Expires 2032-11-23 F2 · derivative.exercise_date: Options fully vest one year from the date of grant on November 23, 2023 Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 18:37 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 54 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026413 · form4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54 F1 · shares: Grant of shares of common stock subject to restrictions that lapse November 23, 2023 Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 17:18 UTC | Nuance Communications, Inc. NUAN · Entity 12406 | Disposition to issuerCommon Stock | 53,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-009444 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest. Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 17:18 UTC | Nuance Communications, Inc. NUAN · Entity 12406 | Disposition to issuerCommon Stock | 4,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-009444 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,492 F1 · shares: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award. F1 · price: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 11,029 | $44.03 | $485,649.88 |
DisclosureSEC source: 0001225208-22-004108 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,290 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.71 to $44.43, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003855 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,481 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,988 | $44.17 | $87,809.96 |
DisclosureSEC source: 0001225208-22-003855 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,319 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003855 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,572 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,572 Underlying: Common Stock · 7,572 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,661 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,323 Underlying: Common Stock · 13,661 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,086 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,259 Underlying: Common Stock · 15,086 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,863 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,591 Underlying: Common Stock · 16,863 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 23,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · derivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,979 Underlying: Common Stock · 23,979 shares Expires 2023-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F4 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F4 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F4 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 53,182 | $42.75 | $2,273,620.91 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,826 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $42.48 to $43.08, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 7,572 | $7.39 | $55,957.08 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,661 | $13.08 | $178,685.88 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 15,086 | $16.31 | $246,052.66 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,863 | $17.26 | $291,055.38 |
DisclosureSEC source: 0001225208-22-003275 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003072 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,661 Underlying: Common Stock · 3,661 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,624 | $42.55 | $69,101.20 |
DisclosureSEC source: 0001225208-22-003072 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,826 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003072 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · derivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,412 Underlying: Common Stock · 3,706 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,644 | $42.55 | $69,952.20 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,789 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 4,583 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,033 | $42.83 | $87,073.39 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,727 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,187 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,187 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F9 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 48,529 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,529 Underlying: Common Stock · 48,529 shares Expires 2032-02-16 F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 16,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,972 Underlying: Common Stock · 16,972 shares Expires 2026-02-16 F6 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 12,187 | $43.70 | $532,580.43 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,177 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.84, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 12,187 | $6.28 | $76,534.36 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 Underlying: Common Stock · 4,153 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,136 | $43.47 | $397,141.92 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,177 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.32 to $43.62, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,219 | $44.01 | $53,648.19 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,313 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 13,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000106 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,193 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 4,057 | $42.48 | $172,341.36 |
DisclosureSEC source: 0001225208-22-000106 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,379 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.